Clinical Trials Logo

Filter by:
NCT ID: NCT00972673 Completed - Asthma Clinical Trials

A Study of GW685698X in Healthy Japanese Male Subjects

Start date: September 24, 2008
Phase: Phase 1
Study type: Interventional

This is a randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects.

NCT ID: NCT00972244 Completed - Clinical trials for Type 2 Diabetes Mellitus

Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

Start date: August 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to obtain information on efficacy and safety of dapagliflozin in Japanese patients with Type 2 Diabetes. This will be done by comparing the effect of dapagliflozin to placebo when given in oral doses.

NCT ID: NCT00972049 Completed - Healthy Clinical Trials

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects

Start date: September 2009
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to assess the safety and tolerability of AZD2516 following administration of a single dose to Japanese healthy subjects.

NCT ID: NCT00971997 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients

SIMPLE
Start date: September 2009
Phase: Phase 4
Study type: Interventional

The purpose is to evaluate the proportion of subjects achieving a Hemoglobin A1c (HbA1c) level below 6.5%, when lispro mix 50/50 is introduced in a stepwise manner from every day (QD) administration to type 2 diabetic patients who have failed to achieve adequate glycemic control on oral antidiabetic drugs (OADs).

NCT ID: NCT00971945 Completed - Breast Cancer Clinical Trials

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer

Start date: June 30, 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of continued administration of paclitaxel given weekly in subjects considered to need to continue treatment after completion of the preceding "Phase II Clinical Study of Weekly Paclitaxel (BMS-181339) with Advanced Breast Cancer (Protocol No. CA139-371)"

NCT ID: NCT00971932 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Start date: July 2009
Phase: Phase 2
Study type: Interventional

The primary objective of this trial is to assess the antitumor activity of cetuximab when given in combination with cisplatin + 5-Fluorouracil (5-FU) for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) in Japanese subjects.

NCT ID: NCT00971867 Completed - Clinical trials for Head and Neck Cancer

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer

Start date: August 4, 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects

NCT ID: NCT00970411 Completed - Solid Tumors Clinical Trials

Study of KRN951 in Patients With Solid Tumors

Start date: August 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of KRN951 administered to patients with solid tumors. In the single dose period, patients in each cohort will receive one oral dose of KRN951 in the first day, followed by a 6-day rest period during which no treatment is received. After that, patients in each cohort will receive one oral dose of KRN951 daily over a 21-day treatment period, followed by a 7-day rest period during which no treatment is received. Treatment will be continued in the absence of disease progression or unacceptable adverse events.

NCT ID: NCT00970281 Completed - Schizophrenia Clinical Trials

A Study of Olanzapine in Patients With Schizophrenia

Start date: September 2009
Phase: Phase 3
Study type: Interventional

The primary objectives of the study is to confirm if the efficacy of intramuscular injection (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with acute psychotic agitation is greater than intramuscular placebo by comparing changes from baseline to 2 hours after the first IM injection of agitation.

NCT ID: NCT00969618 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder

Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess long-term safety and tolerability in adult patients who have completed a previous atomoxetine study.